固定剂量复合剂(FDC)治疗肺结核的疗效和安全性的Meta分析

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (10): 1143-1150.

固定剂量复合剂(FDC)治疗肺结核的疗效和安全性的Meta分析

马婧婧¹, 周泽文¹, 颜陶², 伍翔¹, 王润华¹, 易静¹

¹重庆医科大学公共卫生与管理学院,卫生统计学教研室,重庆 400016;
²重庆医科大学药学院,药理学教研室,重庆 400016

收稿日期:2012-06-01 修回日期:2012-06-25 发布日期:2012-10-19
通讯作者: 易静,通信作者,女,博士,教授,研究生导师,研究方向:人群健康评价。E-mail: yijinga@sina.com
作者简介:马婧婧,女, 在读硕士,研究方向:多元统计方法及其在人群健康评价中的应用。E-mail: vgevge315@163.com
基金资助:
国家自然科学基金“基于人工神经网络的结核病疫情预测研究及软件实现”资助项目(30872160); 重庆市科委自然科学基金计划资助项目(CSTC, 2009BB5415)

Meta-analysis on efficacy and safety of fixed-dose combination (FDC) in treatment of pulmonary tuberculosis

MA Jing-jing¹, ZHOU Ze-wen¹, YAN Tao², WU Xian¹, WANG Run-hua¹, YI Jing¹

¹School of Public Health and Management, Chongqing Medical University, Chongqing 400016, China;
²School of Pharmacy, Chongqing Medical University, Chongqing 400016, China

Received:2012-06-01 Revised:2012-06-25 Published:2012-10-19

摘要/Abstract

摘要： 目的: 评价抗结核固定剂量复合剂治疗肺结核的疗效和安全性。方法: 通过计算机检索和参考文献追溯相结合的方法,收集和整理国内外公开发表的固定剂量复合剂治疗初治涂阳肺结核的疗效或安全性的临床随机对照试验(RCTs)和临床对照试验(CCTs)的文献。结果: 通过筛选纳入22个研究。疗效评价,固定剂量复合剂(FDC)与单药组合治疗初治肺结核在2月末痰菌阴转率、6月末痰菌阴转率比较RR值及其95%CI分别为 1.02(1.01,1.03)、1.01(1.00,1.02),P<0.05;复发率比较RR值及其95%CI为 1.72(0.98,3.02),P>0.05。安全性评价,两组在副反应总发生率、皮肤副反应发生率、胃肠道副反应发生率、肝胆副反应发生率及副反应停药率比较差异均无统计学意义(P>0.05)。经敏感性分析,胃肠道副反应发生率和肝胆副反应发生率的结果不稳定。结论: 固定剂量复合剂治疗肺结核疗效较单药组合好,安全性评价的结果不稳定,需要更多可靠证据。

关键词: 固定剂量复合剂, 肺结核, Meta分析

Abstract: AIM: To evaluate the efficacy and safety of fixed-dose combination for the treatment of pulmonary tuberculosis. METHODS: The studies related to the efficacy and safety of FDC in the treatment of newly diagnosed smear-positive pulmonary tuberculosis, and randomized clinical controlled trials (RCTs) or clinical controlled trials (CCTs) published in the openly journals either in Chinese or English were searched by computer, then searched references of included studies additionally. RESULTS: 22 studies were included. In the aspect of efficacy, Risk Ratio and its 95%CI of 2-month sputum negative conversion rate were 1.02 (1.01,1.03) in FDC regimen, 6-month sputum negative conversion rate were 1.01 (1.00,1.02) in FDC regimen, P<0.05; relapse rate were 1.72 (0.98,3.02) in FDC regimen, P>0.05. As for the evaluation of safety, the total drug adverse event, adverse events of skin , gastrointestinal adverse events, liver and biliary and discontinuation of medication were all no significant differences between FDC regimen and free-drug component regimen (P>0.05). However, adverse events of gastrointestinal and discontinuation, liver and biliary of medication were unsteadiness by sensitivity analysis.CONCLUSION: The efficacy of FDC regimen was better than free-drug component regimen. The result of safety evaluation was unsteadiness, required more credibility evidences.

Key words: Fixed-dose combination, Pulmonary tuberculosis, Meta-analysis

中图分类号:

R311
R521

马婧婧, 周泽文, 颜陶, 伍翔, 王润华, 易静. 固定剂量复合剂(FDC)治疗肺结核的疗效和安全性的Meta分析[J]. 中国临床药理学与治疗学, 2012, 17(10): 1143-1150.

MA Jing-jing, ZHOU Ze-wen, YAN Tao, WU Xian, WANG Run-hua, YI Jing. Meta-analysis on efficacy and safety of fixed-dose combination (FDC) in treatment of pulmonary tuberculosis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(10): 1143-1150.

参考文献

[1] The Global Plan to Stop TB, 2006-2015. actions for life: towards a world free of tuberculosis[J]. Int J Tuberc Lung Dis, 2006, 10(3): 240-241.
[2] Zignol M, Hosseini MS, Wright A, et al.Global incidence of multidrug-resistant tuberculosis[J]. J Infect Dis, 2006, 194(4): 479-485.
[3] The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization[J]. Tuber Lung Dis, 1994, 75(3): 180-181.
[4] Girling DJ, Caulet P, Pamra SP, et al.Anti-tuberculosis regimens of chemotherapy. Recommendations from the Committee on Treatment of the International Union against Tuberculosis and Lung Disease[J]. Indian J Chest Dis Allied Sci, 1988, 30(4): 296-304.
[5] 张斯钰. FDC与板式组合药治疗肺结核的临床随机对照试验研究[D]. 中南大学, 2010.
[6] Higgins Jpt G S E. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March2011].The Cochrane Collaboration,2011.Available from www.cochrane-handbook.org.
[7] 陈瑜晖. 四联抗结核固定剂量复合剂临床治疗效果分析[D]. 暨南大学, 2009.
[8] 谭卫国. 在结核病控制中应该固定剂量复合剂(FDC)的相关研究[D]. 北京市结核病胸部肿瘤研究所, 2007.
[9] 蔡薛芳, 冯月娟. 国产固定剂量复合剂治疗初治涂阳肺结核疗效观察[J]. 浙江预防医学, 2010, 22(7): 21-23.
[10] 杜鹃, 田丹, 张正斌. 抗结核固定剂量复合剂治疗初治涂阳肺结核效果研究[J]. 公共卫生与预防医学, 2011,22(4): 35-38.
[11] 杜永成, 陈求扬, 林淑芳, 等. 不含链霉素的固定复合制剂在初治涂阳肺结核病人中的应用研究[J]. 海峡预防医学杂志, 2007,13(6): 89-90.
[12] 梁云,颜晓霞,王建云,等. 抗结核固定剂量复合剂治疗初治肺结核的疗效观察[J]. 中国防痨杂志, 2007, 29(2): 180-181.
[13] 马丽萍,吴晓光,初乃惠,等. 在DOTS管理下应用国产4药固定剂量复合剂治疗初治菌阳肺结核的可行性研究[J]. 中国防痨杂志, 2010,61(5): 21-25.
[14] 邱志红,张思潮. 国产抗结核固定剂量复合剂与板式组合药的运用研究[J]. 中国预防医学杂志, 2010,11(6): 605-607.
[15] 王健,赵锦,钟涛. 国产固定剂量复合剂与板式组合药治疗肺结核临床近期效果评价[J]. 现代预防医学, 2007,33(13): 2590-2591.
[16] 许卫国,陆伟,何洪江,等. 国产抗结核固定剂量复合剂治疗初治涂阳肺结核患者的近期疗效观察[J]. 中华结核和呼吸杂志, 2004,52(10): 45-48.
[17] 赵庆蓉,田明,潘蓉,等. 国产固定剂量四/二药复合剂治疗初治涂阳肺结核患者近期疗效观察[J]. 寄生虫病与感染性疾病, 2007,15(3): 122-127.
[18] 赵晓春. 固定剂量复合剂治疗肺结核疗效观察[J]. 中国防痨杂志, 2006,57(2): 114-115.
[19] 钟球,黄桂清,张明,等. 固定剂量复合剂在省结核病防治规划中应用的研究[J]. 中国防痨杂志, 2006,57(5): 274-277.
[20] 朱莉贞,严碧涯. 固定剂量复合剂卫非特/卫非宁治疗结核病的临床对照研究[J]. 中华结核和呼吸杂志, 1998, 21(11): 645-647.
[21] 朱莉贞,严碧涯. 固定剂量复合剂卫非特/卫非宁治疗结核病的临床对照研究--二年随访结果[J]. 结核病与胸部肿瘤, 2000,48(5): 320.
[22] 黄诚. 抗结核固定剂量复合剂治疗肺结核疗效观察[J]. 江苏预防医学, 2005, 16(3): 31-33.
[23] Su WJ, Perng RP.Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up[J]. Int J Tuberc Lung Dis, 2002, 6(11): 1029-1032.
[24] Bartacek A, Schutt D, Panosch B, et al.Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis[J]. Int J Tuberc Lung Dis, 2009, 13(6): 760-766.
[25] Bartacek A, Schutt D, Panosch B, et al.Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis[J]. Int J Tuberc Lung Dis, 2009, 13(6): 760-766.
[26] Gravendeel JM, Asapa AS, Becx-Bleumink M, et al.Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia[J]. Tuberculosis (Edinb), 2003, 83(1-3): 183-186.
[27] Suryanto AA, van den Broek J, Hatta M, et al. Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia[J]? Int J Tuberc Lung Dis, 2008, 12(2): 174-179.
[28] Lienhardt C, Cook SV, Burgos M, et al.Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: The study C randomized controlled trial[J]. JAMA,2011, 305(14): 1415-1423.
[29] Zaka-Ur-Rehman Z, Jamshaid M, Chaudhry A. Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients[J]. Pak J Pharm Sci, 2008, 21(2): 185-194.
[30] Norval PY, Blomberg B, Kitler ME, et al. Estimate of the global market for rifampicin-containing fixed-dose combination tablets[J]. Int J Tuberc Lung Dis, 1999, 3(11 Suppl 3): S292-S300, S317-S321.